[Pamplona, Spain], October 27, 2025 – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs for orphan diseases, announced today the achievement of...

Navarra, Spain – August 28, 2025 — Palobiofarma is pleased to announce the successful completion of the industrial research project titled “Investigation of Dual Antagonist Compounds Targeting A2A and...

Palobiofarma and Medibiofarma open new headquarters in the AIN building in Cordovilla, Spain Pamplona-Iruña, February 27, 2025 – The Navarra biotechnology companies, Palobiofarma and Medibiofarma,...

Palobiofarma S.L. Announces Positive Top-Line Results from the Phase 2 Trial of Oral PBF-680 in Moderate-to-Severe COPD patients. Primary endpoint was achieved, with PBF-680 demonstrating a statistically...

Pamplona, Spain – Palobiofarma S.L. is pleased to announce the “last patient last visit” of the Phase II trial investigating the safety and preliminary efficacy of PBF-680 in moderate to severe COPD...

Pamplona, Spain – Palobiofarma S.L. is pleased to announce that the FDA and the EMA have granted Orphan Drug Designation to our novel therapeutic candidate, PBF-999, for the treatment of Prader-Willi...

Pamplona-Iruña, February 2, 2024.- Palobiofarma has closed a seven-million-euro investment round led by Inveready, through the Inveready Biotech IV fund, the public company Sodena and the company’s...

Pamplona, Spain November 6, 2023  Palobiofarma S.L. announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) Designation for the company’s phosphodiesterase 10...

[Pamplona, Spain], [May 9th, 2023] – Palobiofarma S.L., a biopharmaceutical company dedicated to the discovery and development of innovative drugs, has enrolled the first three patients in a clinical study...